Tenvie Therapeutics initiates Phase I trial of NLRP3 inhibitor in obesity

Tenvie Therapeutics, a California-based biotech, [announced](https://www.globenewswire.com/news-release/2026/04/06/3268373/0/en/Tenvie-Therapeutics-Announces-Dosing-of-First-Subject-in-Phase-1-Clinical-Trial-of-TNV262-a-Fully-CNS-Penetrant-NLRP3-Inhibitor.html) the dosing of the first subject in a Phase I/Ib clinical study of TNV262, a small molecule NLRP3 inhibitor, in healthy volunteers and adults with obesity. The announcement, made April 6, 2026, marks trial initiation only; no safety, pharmacokinetic, or efficacy data were reported. The Phase Ia/Ib study is designed as a single and multiple ascending dose evaluation, with primary endpoints covering safety, tolerability, and biomarkers of inflammation and cardiometabolic risk. Secondary endpoints include body weight, body composition, and measures of appetite and eating behavior in participants with obesity. The company said preliminary safety and pharmacokinetic data are expected in the second half of 2026. No dosing details, enrollment targets, or blinding status were disclosed in the announcement. The trial enrolls healthy volunteers alongside persons with obesity, though the total planned sample size was not stated. No NCT registration number was included in the press release; a registry record had not been publicly indexed at the time of reporting. Tenvie referenced preclinical data showing complete CNS penetrance and suppression of inflammatory cardiovascular risk biomarkers, though the company did not disclose the species, models, or study designs underlying those findings. TNV262 inhibits NLRP3, a sensor/component that forms the NLRP3 inflammasome complex upon activation by metabolic stressors (e.g., saturated fatty acids, hyperglycemia), triggering caspase-1 activation and the release of pro-inflammatory cytokines IL-1β and IL-18. Preclinical and translational studies support a mechanistic link between NLRP3 activation and obesity-associated pathologies, with chronic activation of NLRP3 in adipose tissue, liver, and [other organs ](https://app.allsci.com/hypothesis/ASC-HY-0000013636344-1.0-1760368185)found to contribute to the inflammatory [milieu of obesity](https://app.allsci.com/hypothesis/ASC-HY-0000014726888-1.0-1765390813), promoting insulin resistance, dyslipidemia, and tissue dysfunction. Most NLRP3-targeting assets are in early-stage development or are being evaluated for other inflammatory or metabolic indications. Tenvie's stated rationale centers on CNS penetrance, which the company argues has been a limitation of earlier NLRP3 programs. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/nlrp3-inhibitor-obesity-trial-tenvie-therapeutics)